JonesTrading analyst Debanjana Chatterjee has maintained their bullish stance on KALV stock, giving a Buy rating yesterday.
Debanjana Chatterjee’s rating is based on several key factors surrounding KalVista Pharmaceuticals. The anticipation of an FDA approval for sebetralstat by mid-June is a significant driver, as the review process has been smooth without any disruptions. This potential approval is expected to enhance the company’s market position and drive stock value.
Additionally, recent analyses have shown sebetralstat to be effective in treating laryngeal attacks, which, despite being rare, are a critical concern for patients. The company’s strong cash position further supports its operational and strategic initiatives, including the upcoming launch plans. These elements combined provide a solid foundation for the Buy rating, reflecting confidence in KalVista’s future performance and growth potential.
According to TipRanks, Chatterjee is a 2-star analyst with an average return of -0.3% and a 23.68% success rate. Chatterjee covers the Healthcare sector, focusing on stocks such as EyePoint Pharmaceuticals, Opthea Limited Sponsored ADR, and Sagimet Biosciences, Inc. Class A.
In another report released yesterday, JMP Securities also reiterated a Buy rating on the stock with a $19.00 price target.